文献速递头颈部肿瘤放疗

尼莫拉唑联合加速放化疗治疗局部晚期HPV阴性头颈鳞癌的国际随机对照试验

An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC).
PubMed 文献 · Radiother Oncol · 2025-10-23

这项国际多中心随机安慰剂对照试验评估低氧放射增敏剂尼莫拉唑联合加速同步放化疗对局部晚期HPV阴性头颈鳞癌的疗效。研究因提前终止仅纳入194例(计划640例),尼莫拉唑组3年局部区域失败率为20.7%,安慰剂组为33.8%,多因素分析显示尼莫拉唑显著改善局部区域控制(校正HR 0.51),但未显著改善生存。

要点

  • 尼莫拉唑联合加速放化疗显著改善局部区域控制,校正HR 0.51(95%CI 0.27-0.95)。
  • 3年局部区域失败率尼莫拉唑组20.7% vs 安慰剂组33.8%,但总生存无显著差异。
  • 研究因提前终止仅纳入194/640例,限制进一步详细分析。

核心结论

  • 尼莫拉唑改善了晚期HPV阴性头颈鳞癌的局部区域控制,但未显著改善生存。

研究设计与样本

  • 国际多中心随机安慰剂对照试验,计划入组640例,实际因提前终止纳入194例(尼莫拉唑组97例,安慰剂组97例)。
  • 入组III-IV期喉、下咽或HPV阴性口咽鳞癌患者,随机接受尼莫拉唑或安慰剂联合IMRT中度加速同步放化疗(70 Gy/6周)。
  • 尼莫拉唑/安慰剂剂量为每日1.2 mg/m2,顺铂总剂量200 mg/m2(每周40 mg/m2或每3周100 mg/m2)。

主要发现

  • 3年局部区域失败率尼莫拉唑组为20.7%(95%CI 12.8-29.8),安慰剂组为33.8%(95%CI 24.1-43.8)。
  • 3年疾病特异性生存率尼莫拉唑组76.7%,安慰剂组74.3%;总生存率分别为62.4%和61.5%。
  • 多因素分析显示尼莫拉唑显著改善局部区域控制(校正HR 0.51;95%CI 0.27-0.95),良好WHO体能状态和每周顺铂亦为有利因素。
  • 治疗依从性和治疗相关发病率在尼莫拉唑/安慰剂组及顺铂方案间无显著差异,但每3周顺铂方案急性肾毒性更高。

临床怎么用

  • 对于局部晚期HPV阴性头颈鳞癌,尼莫拉唑联合加速放化疗可考虑作为改善局部区域控制的策略。
  • 每周顺铂方案与更好的局部区域控制相关,且每3周方案急性肾毒性更高。

局限性

  • 研究因提前终止仅纳入194/640例,样本量不足,限制了进一步详细分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the benefit of the hypoxic radiosensitizer nimorazole (NIM) with accelerated concomitant chemo-radiotherapy in patients with advanced squamous cell carcinoma of the head and neck (HNSCC). MATERIALS AND METHODS: Patients with stage III-IV laryngeal, hypopharyngeal or HPV-negative oropharyngeal SCC were randomized between NIM or placebo, given concomitantly with moderately accelerated chemo-radiotherapy delivered using IMRT (70 Gy in 6 weeks). Total cisplatin dose was 200 mg/m2 either weekly (40 mg/m2) or 3-weekly (100 mg/m2). NIM/placebo was given with 1.2 mg/m2 daily. RESULTS: Between Aug 2014 and Jan 2018, when the trial closed prematurely, a total of 194 patients (92 oropharynx, 59 hypopharynx and 43 larynx) were randomized (97 NIM, 97 placebo) out of 640 planned. Most patients had T3-T4 (76%) and N2-3 (66%) tumors. The three-year incidence of locoregional failure was 20.7% (95% Cl: 12.8-29.8) in the NIM arm and 33.8% (24.1-43.8) in the placebo arm. Corresponding disease specific survival were 76.7% and 74.3% and overall survival 62.4% and 61.5% for NIM and placebo, respectively. Multivariable analysis demonstrated significant locoregional benefit of NIM (adjusted HR 0.51; 95% Cl: 0.27-0.95) together with good WHO performance and weekly cisplatin. Compliance with treatment did not differ significantly depending on NIM/placebo allocation and cisplatin regimen, nor did treatment related morbidity except for acute nephrotoxicity which appeared to be higher in the 3-weekly cisplatin regimen. CONCLUSION: NIM improved locoregional control in advanced HPV-negative HNSCC, but without significant survival improvement. This finding underscore that hypoxic radiosensitization plays a role in chemo-radiotherapy for HNSCC. The incompleteness of the study precluded further detailed analysis.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Grégoire V, Tao Y, Kaanders J, et al. An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC). Radiother Oncol. 2025. PMID: 41138857. doi:10.1016/j.radonc.2025.111227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。